Roche said its experimental obesity drug enicepatide helped overweight or obese patients with type 2 diabetes lose an average of 15.5% of their body weight in a mid-stage trial. The once-weekly injection mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar. At the highest 24-milligram dose, patients achieved significant reductions in HbA1c after 48 weeks, meeting the study’s two main goals. Roche said about 62% of participants reached HbA1c below 5.7%, a level in the non-diabetic range. About 2% of the 447 participants receiving enicepatide discontinued treatment because of side effects, compared with none in the placebo group; most gastrointestinal effects were mild to moderate. Roche is competing with AstraZeneca and Amgen to challenge obesity-market leaders Eli Lilly and Novo Nordisk. The company plans to begin late-stage glycemic-control and cardiovascular-outcomes studies in the first half of 2027. A June mid-stage trial found enicepatide helped people without diabetes lose 22.7% of their body weight.